平滑筋肉腫治療薬の世界市場レポート2025年

平滑筋肉腫治療薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は8.4%で、16億3,000万米ドルに達する見込みです。/b>予測期間の成長は、免疫療法に基づく新薬候補の採用の増加、希少がんの治療におけるゲノムおよび分子プロファイリングの利用の拡大、希少薬のパイプラインと規制指定の増加、個別化治療戦略に対する需要の高まり、患者擁護および支援ネットワークの強化に起因すると考えられます。この期間に予想される主な動向には、技術主導型の薬剤スクリーニング、マルチターゲット療法の開発、ゲノムデータの治療計画への組み込み、集学的治療モデルの採用、モノクローナル抗体療法の進歩などがあります。

腫瘍学調査への投資の増加は、今後数年間における同市場の成長を牽引すると予想されます。がん研究とは、がんの原因、研究開発、診断、治療、予防を科学的に探求することです。このような投資が増加している背景には、世界のがん罹患率の上昇が大きく寄与しています。平滑筋肉腫治療薬の開発は、標的治療の技術革新を促進し、希少がん治療の進歩のための資金を集めることで、がん研究に貢献しています。例えば、2023年、米国放射線腫瘍学会（ASTRO）は、米国国立衛生研究所（NIH）が510億米ドルの資金を獲得し、その内、米国国立がん研究所（NCI）が99億8,800万米ドルで、前年度より27億米ドル増加したと報告しました。このように、腫瘍学研究への投資の増加は、平滑筋肉腫治療薬市場の成長に重要な役割を果たしています。

平滑筋肉腫治療薬市場の主要企業は、ルルビネクチンをベースとしたレジメンなどの革新的な標的治療薬の市場開拓に注力し、進行腫瘍や治療抵抗性腫瘍の患者の治療成績を向上させています。ルルビネクテジンベースのレジメンでは、平滑筋肉腫細胞を特異的に攻撃し、治療効果を向上させるように設計された標的抗がん剤であるルルビネクテジンを使用します。例えば、2023年10月、スペインに本社を置く製薬会社Pharma Mar S.A.は、転移性平滑筋肉腫（LMS）患者に対するZepzelca（ルルビネクテジン）とドキソルビシンとの併用療法の有効性を評価するSaLuDo第IIb/III相臨床試験を開始しました。この試験は、無増悪生存期間や全生存期間といった主要な指標に焦点を当て、併用療法が現在の治療選択肢と比較して優れた結果をもたらすかどうかを明らかにすることを目的としています。SaLuDo試験が成功すれば、転移性平滑筋肉腫と闘う患者に新たな希望をもたらし、新たな標準治療となる可能性があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の平滑筋肉腫治療薬：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の平滑筋肉腫治療薬市場：成長率分析
• 世界の平滑筋肉腫治療薬市場の実績：規模と成長, 2019-2024
• 世界の平滑筋肉腫治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の平滑筋肉腫治療薬：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の平滑筋肉腫治療薬市場：薬剤タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法剤
• 標的療法
• 免疫療法
• 放射線治療
• 併用療法
• 世界の平滑筋肉腫治療薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アントラサイクリン
• アルキル化剤
• 代謝拮抗剤
• その他の薬物クラス
• 世界の平滑筋肉腫治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口
• 静脈
• 皮下
• 外用
• 筋肉
• 世界の平滑筋肉腫治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の平滑筋肉腫治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 研究ラボ
• 在宅ケア環境
• 製薬会社
• 世界の平滑筋肉腫治療薬市場、化学療法剤のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アントラサイクリン
• アルキル化剤
• 代謝拮抗剤
• トポイソメラーゼ阻害剤
• タキサン
• 世界の平滑筋肉腫治療薬市場、標的療法のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• デオキシリボ核酸マイナーグルーブバインダー
• チロシンキナーゼ阻害剤
• ラパマイシン阻害剤のメカニズム標的
• 血管内皮増殖因子阻害剤
• 世界の平滑筋肉腫治療薬市場、免疫療法のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫チェックポイント阻害剤
• がんワクチン
• 養子細胞移植
• 世界の平滑筋肉腫治療薬市場、放射線治療のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部放射線療法
• 定位放射線治療
• 強度変調放射線治療
• 世界の平滑筋肉腫治療薬市場、併用療法のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法+ 標的療法
• 化学療法＋放射線療法
• 免疫療法+ 標的療法

第7章 地域別・国別分析

• 世界の平滑筋肉腫治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の平滑筋肉腫治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 平滑筋肉腫治療薬市場：競合情勢
• 平滑筋肉腫治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca Plc
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly And Co
• Philogen S.p.A
• Eisai Co. Ltd
• Incyte Corp
• PharmaMar SA
• Karyopharm Therapeutics Inc.
• Taiho Pharmaceutical Co. Ltd.
• Agenus Inc.
• Adaptimmune Therapeutics plc
• BioInvent International AB
• Advenchen Laboratories LLC
• Radiopharm Theranostics Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 平滑筋肉腫治療薬市場2029：新たな機会を提供する国
• 平滑筋肉腫治療薬市場2029：新たな機会を提供するセグメント
• 平滑筋肉腫治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Leiomyosarcoma drugs are pharmaceutical treatments specifically designed to manage or inhibit the progression of leiomyosarcoma, a rare type of cancer that arises from smooth muscle tissue. These drugs function by targeting the biological mechanisms that allow tumor cells to grow, multiply, and spread within the body.

The primary types of leiomyosarcoma treatments include chemotherapy agents, targeted therapies, immunotherapies, radiation therapies, and combination therapies. Chemotherapy agents are used to destroy or inhibit cancer cell growth by disrupting their division and multiplication processes. These agents belong to various classes, including anthracyclines, alkylating agents, antimetabolites, and others, and are administered through different routes such as oral, intravenous, subcutaneous, topical, and intramuscular methods. Distribution channels for these drugs include hospital pharmacies, retail pharmacies, online pharmacies, and others, catering to end users like hospitals, specialty clinics, research laboratories, homecare settings, and pharmaceutical companies.

The leiomyosarcoma drug market research report is one of a series of new reports from The Business Research Company that cover leiomyosarcoma drug market statistics, including the leiomyosarcoma drug industry's global market size, regional shares, competitors with the leiomyosarcoma drug market share, detailed leiomyosarcoma drug market segments, market trends and opportunities, and any further data you may need to thrive in the leiomyosarcoma drug market. This leiomyosarcoma drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The leiomyosarcoma drug market size has grown strongly in recent years. It will grow from $1.09 billion in 2024 to $1.18 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%./b> Growth during the historic period can be attributed to the rising incidence of uterine and soft tissue sarcomas, greater awareness among clinicians regarding rare cancers, increased patient participation in early-phase clinical trials, expanded off-label use of existing oncology drugs, and the growing utilization of radiologic imaging in cancer diagnostics.

The leiomyosarcoma drug market size is expected to see strong growth in the next few years. It will grow to $1.63 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%./b> Growth in the forecast period can be attributed to the increasing adoption of immunotherapy-based drug candidates, expanded use of genomic and molecular profiling in treating rare cancers, a growing pipeline of orphan drugs and regulatory designations, rising demand for personalized treatment strategies, and the strengthening of patient advocacy and support networks. Key trends expected during this period include technology-driven drug screening, the development of multi-targeted therapies, incorporation of genomic data into treatment planning, adoption of multidisciplinary care models, and advancements in monoclonal antibody therapies.

The increasing investment in oncology research is expected to drive the growth of the leiomyosarcoma drug market in the coming years. Oncology research involves the scientific exploration of the causes, development, diagnosis, treatment, and prevention of cancer. This growing investment is largely fueled by the rising global burden of cancer, which necessitates advanced therapies and better patient outcomes. The development of leiomyosarcoma drugs contributes to oncology research by promoting innovation in targeted treatments and attracting funding for advancements in rare cancer therapies. For example, in 2023, the American Society for Radiation Oncology (ASTRO) reported that the National Institutes of Health (NIH) received $51 billion in funding, including $9.988 billion for the National Cancer Institute (NCI), representing a $2.7 billion increase from the prior fiscal year. Thus, increasing investment in oncology research is playing a significant role in the growth of the leiomyosarcoma drug market.

Leading companies in the leiomyosarcoma drug market are concentrating on the development of innovative targeted therapies, such as lurbinectedin-based regimens, to enhance treatment outcomes for patients with advanced or treatment-resistant tumors. Lurbinectedin-based regimens involve the use of lurbinectedin, a targeted cancer drug designed to specifically attack leiomyosarcoma cells and improve therapeutic efficacy. For example, in October 2023, Pharma Mar S.A., a pharmaceutical company based in Spain, launched the SaLuDo Phase IIb/III clinical trial to assess the effectiveness of Zepzelca (lurbinectedin) in combination with doxorubicin for patients with metastatic leiomyosarcoma (LMS). This trial aims to determine whether the combination therapy offers superior results compared to current treatment options, focusing on key metrics such as progression-free survival and overall survival. If proven successful, the SaLuDo trial could set a new standard of care, offering new hope to patients battling metastatic leiomyosarcoma.

In December 2023, Pfizer Inc., a pharmaceutical company based in the United States, acquired Seagen Inc. for $43 billion. This acquisition is intended to bolster Pfizer's position in the oncology sector by utilizing Seagen's antibody-drug conjugate (ADC) technology to enhance its cancer treatment portfolio and support sustained revenue growth. Seagen Inc. is a U.S.-based biotechnology firm specializing in the development and commercialization of cancer therapies.

Major players in the leiomyosarcoma drug market are Pfizer Inc., Johnson And Johnson, Merck And Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly And Co, Philogen S.p.A, Eisai Co. Ltd, Incyte Corp, PharmaMar SA, Karyopharm Therapeutics Inc., Taiho Pharmaceutical Co. Ltd., Agenus Inc., Adaptimmune Therapeutics plc, BioInvent International AB, Advenchen Laboratories LLC, and Radiopharm Theranostics Limited.

North America was the largest region in the leiomyosarcoma drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leiomyosarcoma drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the leiomyosarcoma drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The leiomyosarcoma drug market consists of sales of trabectedin, pazopanib, doxorubicin, gemcitabine, and eribulin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Leiomyosarcoma Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on leiomyosarcoma drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for leiomyosarcoma drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The leiomyosarcoma drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Chemotherapy Agents; Targeted Therapy; Immunotherapy; Radiation Therapy; Combination Therapy
• 2) By Drug Class: Anthracyclines; Alkylating Agents; Antimetabolites; Other Drug Class
• 3) By Route of Administration: Oral; Intravenous; Subcutaneous; Topical; Intramuscular
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 5) By End User: Hospitals; Specialized Clinics; Research Laboratories; Homecare Settings; Pharmaceutical Companies

Subsegments

• 1) By Chemotherapy Agents: Anthracyclines; Alkylating Agents; Antimetabolites; Topoisomerase Inhibitors; Taxanes
• 2) By Targeted Therapy: Deoxyribonucleic Acid Minor Groove Binders; Tyrosine Kinase Inhibitors; Mechanistic Target Of Rapamycin Inhibitors; Vascular Endothelial Growth Factor Inhibitors
• 3) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines; Adoptive Cell Transfer
• 4) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy; Intensity-Modulated Radiation Therapy
• 5) By Combination Therapy: Chemotherapy + Targeted Therapy; Chemotherapy + Radiation Therapy; Immunotherapy + Targeted Therapy
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Merck And Co. Inc.; Bayer AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Leiomyosarcoma Drug Market Characteristics

3. Leiomyosarcoma Drug Market Trends And Strategies

4. Leiomyosarcoma Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Leiomyosarcoma Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Leiomyosarcoma Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Leiomyosarcoma Drug Market Growth Rate Analysis
• 5.4. Global Leiomyosarcoma Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Leiomyosarcoma Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Leiomyosarcoma Drug Total Addressable Market (TAM)

6. Leiomyosarcoma Drug Market Segmentation

• 6.1. Global Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Agents
• Targeted Therapy
• Immunotherapy
• Radiation Therapy
• Combination Therapy
• 6.2. Global Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anthracyclines
• Alkylating Agents
• Antimetabolites
• Other Drug Class
• 6.3. Global Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Subcutaneous
• Topical
• Intramuscular
• 6.4. Global Leiomyosarcoma Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.5. Global Leiomyosarcoma Drug Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialized Clinics
• Research Laboratories
• Homecare Settings
• Pharmaceutical Companies
• 6.6. Global Leiomyosarcoma Drug Market, Sub-Segmentation Of Chemotherapy Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anthracyclines
• Alkylating Agents
• Antimetabolites
• Topoisomerase Inhibitors
• Taxanes
• 6.7. Global Leiomyosarcoma Drug Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Deoxyribonucleic Acid Minor Groove Binders
• Tyrosine Kinase Inhibitors
• Mechanistic Target Of Rapamycin Inhibitors
• Vascular Endothelial Growth Factor Inhibitors
• 6.8. Global Leiomyosarcoma Drug Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors
• Cancer Vaccines
• Adoptive Cell Transfer
• 6.9. Global Leiomyosarcoma Drug Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy
• Stereotactic Body Radiation Therapy
• Intensity-Modulated Radiation Therapy
• 6.10. Global Leiomyosarcoma Drug Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy + Targeted Therapy
• Chemotherapy + Radiation Therapy
• Immunotherapy + Targeted Therapy

7. Leiomyosarcoma Drug Market Regional And Country Analysis

• 7.1. Global Leiomyosarcoma Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Leiomyosarcoma Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Leiomyosarcoma Drug Market

• 8.1. Asia-Pacific Leiomyosarcoma Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Leiomyosarcoma Drug Market

• 9.1. China Leiomyosarcoma Drug Market Overview
• 9.2. China Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Leiomyosarcoma Drug Market

• 10.1. India Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Leiomyosarcoma Drug Market

• 11.1. Japan Leiomyosarcoma Drug Market Overview
• 11.2. Japan Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Leiomyosarcoma Drug Market

• 12.1. Australia Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Leiomyosarcoma Drug Market

• 13.1. Indonesia Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Leiomyosarcoma Drug Market

• 14.1. South Korea Leiomyosarcoma Drug Market Overview
• 14.2. South Korea Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Leiomyosarcoma Drug Market

• 15.1. Western Europe Leiomyosarcoma Drug Market Overview
• 15.2. Western Europe Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Leiomyosarcoma Drug Market

• 16.1. UK Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Leiomyosarcoma Drug Market

• 17.1. Germany Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Leiomyosarcoma Drug Market

• 18.1. France Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Leiomyosarcoma Drug Market

• 19.1. Italy Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Leiomyosarcoma Drug Market

• 20.1. Spain Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Leiomyosarcoma Drug Market

• 21.1. Eastern Europe Leiomyosarcoma Drug Market Overview
• 21.2. Eastern Europe Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Leiomyosarcoma Drug Market

• 22.1. Russia Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Leiomyosarcoma Drug Market

• 23.1. North America Leiomyosarcoma Drug Market Overview
• 23.2. North America Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Leiomyosarcoma Drug Market

• 24.1. USA Leiomyosarcoma Drug Market Overview
• 24.2. USA Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Leiomyosarcoma Drug Market

• 25.1. Canada Leiomyosarcoma Drug Market Overview
• 25.2. Canada Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Leiomyosarcoma Drug Market

• 26.1. South America Leiomyosarcoma Drug Market Overview
• 26.2. South America Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Leiomyosarcoma Drug Market

• 27.1. Brazil Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Leiomyosarcoma Drug Market

• 28.1. Middle East Leiomyosarcoma Drug Market Overview
• 28.2. Middle East Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Leiomyosarcoma Drug Market

• 29.1. Africa Leiomyosarcoma Drug Market Overview
• 29.2. Africa Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Leiomyosarcoma Drug Market Competitive Landscape And Company Profiles

• 30.1. Leiomyosarcoma Drug Market Competitive Landscape
• 30.2. Leiomyosarcoma Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Leiomyosarcoma Drug Market Other Major And Innovative Companies

• 31.1. AstraZeneca Plc
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly And Co
• 31.5. Philogen S.p.A
• 31.6. Eisai Co. Ltd
• 31.7. Incyte Corp
• 31.8. PharmaMar SA
• 31.9. Karyopharm Therapeutics Inc.
• 31.10. Taiho Pharmaceutical Co. Ltd.
• 31.11. Agenus Inc.
• 31.12. Adaptimmune Therapeutics plc
• 31.13. BioInvent International AB
• 31.14. Advenchen Laboratories LLC
• 31.15. Radiopharm Theranostics Limited

32. Global Leiomyosarcoma Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Leiomyosarcoma Drug Market

34. Recent Developments In The Leiomyosarcoma Drug Market

35. Leiomyosarcoma Drug Market High Potential Countries, Segments and Strategies

• 35.1 Leiomyosarcoma Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Leiomyosarcoma Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Leiomyosarcoma Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer